Newcastle disease DNA vaccine nano composite adjuvant as well as preparation method and application thereof

Through nanocomplex adjuvants of aluminum-magnesium hydrotalcite and okra polysaccharide RPS-1, the problem of limited immune mode and low immunogenicity of the Newcastle vaccine is solved, and the immune activity and protection rate of DNA vaccines is enhanced, with prevention and control in order to achieve the prevention and control of DNA vaccines. Promotional value on infectious diseases in animals.

CN118987196AInactive Publication Date: 2024-11-22HAINAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411110167.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Newcastle vaccine has problems such as limited immune mode, low immunogenicity, easy degradation of DNA vaccines, and poor immune effect. It is necessary to have an adjuvant that can enhance the immune activity and protection rate of DNA vaccines.

Method used

Nanocomplex adjuvant of aluminum-magnesium hydrotalcite (LDH) nanoparticles and okra polysaccharide RPS-1 is used to protect the vaccine as a carrier and enhance its immune activity by combining the Newcastle Disease DNA vaccine with it.

Benefits of technology

Effectively protect DNA vaccines from degradation, enhance the immune function and disease resistance of animals, improve the protection rate of vaccines, and have promotional value for preventing and controlling infectious diseases in animals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987196A_ABST
    Figure CN118987196A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of vaccine adjuvants, in particular to a Newcastle disease DNA vaccine nano-composite adjuvant and a preparation method and application thereof.The composite adjuvant comprises an agent A and an agent B. The agent A is an aluminum-magnesium hydrotalcite nano-particle solution, the agent B is an okra polysaccharide RPS-1 solution, and the agent A is prepared by taking magnesium chloride hexahydrate and aluminum chloride hexahydrate as raw materials through a one-step method. The agent B is prepared by taking fresh okra fruits as raw materials and adopting a water extraction and alcohol precipitation method; the composite adjuvant is used as a loading agent to be matched with a Newcastle disease nucleic acid vaccine for preventing and treating Newcastle disease. According to the present invention, the aluminum-magnesium hydrotalcite and the okra polysaccharide RPS-1 are combined in the composite form, such that the antibody level and the thymus index of the chicken can be improved, and the product can be adopted as the immunopotentiator of the Newcastle disease DNA vaccine, can be adopted as the carrier to protect the DNA vaccine from degradation, can increase the immunocompetence of the DNA vaccine, and can enhance the animal immune function; the method has a certain popularization value in prevention and control of animal infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of vaccine adjuvants, and in particular to an aluminum magnesium hydrotalcite (LDH)-okra polysaccharide nano composite adjuvant for Newcastle disease HN gene recombinant DNA nucleic acid vaccine, and a preparation method and application thereof. Background Art

[0002] As a highly pathogenic infectious disease caused by Newcastle disease virus (NDV), Newcastle disease (ND) can cause infection and death in a variety of poultry species, including chickens, turkeys, ducks, pigeons and parrots. It has the characteristics of rapid onset, high mortality rate and strong infectivity, causing huge losses to the world's poultry industry. It belongs to Class I infectious diseases and is also the fourth most problematic disease in poultry, second only to highly pathogenic avian influenza, avian infectious bronchitis and low pathogenic influenza. It is reported that in addition to poultry, NDV can infect at least 26 other poultry species, mainly through respiratory and digestive tract infections.

[0003] Vaccines are still the main means of prevention and control of Newcastle disease. Vaccines used to prevent and control Newcastle disease include inactivated vaccines and live attenuated vaccines. Although inactivated vaccines and live attenuated vaccines can play a good preventive role in poultry, they both have some disadvantages. After vaccination with inactivated vaccines, high levels of antibodies can be produced, but IgA and IgG are not present, and IgG cannot be transported to the lungs. After nasal drops, eye drops, and aerosol immunization, attenuated vaccines can not only stimulate the production of secretory IgA and IgG in the respiratory tract, digestive tract, and Harderian glands, but also produce high levels of IgG antibodies. However, attenuated vaccines will excrete toxins into the environment, and viral gene mutations are prone to occur under high levels of immunization and disinfection.

[0004] With the development of genetic engineering technology, new nucleic acid vaccines (DNA vaccines) developed using genetic engineering technology have become a hot topic in modern vaccine research due to their many advantages such as non-pathogenicity, simple preparation, no interference from maternal antibodies, and the ability to activate humoral and cellular immunity. However, studies have also found that nucleic acid vaccines have limited immunization methods, low immunogenicity, are easily degraded in the body, and have poor immune effects, often requiring high-dose multiple immunizations. Selecting a suitable adjuvant as a delivery vehicle to load the DNA vaccine and the adjuvant, enhancing the immunogenicity of the DNA vaccine, and improving the immune effect has become one of the urgent issues that researchers need to solve. Summary of the invention

[0005] The purpose of the present invention is to provide a Newcastle disease DNA vaccine nanocomposite adjuvant, which can not only serve as a carrier to protect the DNA vaccine from degradation, but also increase its immune activity, enhance the animal immune function, improve the animal's disease resistance and the vaccine's protection rate, and thus has great promotion value in preventing and controlling animal infectious diseases.

[0006] The technical solution adopted by the present invention is:

[0007] A Newcastle disease DNA vaccine nanocomposite adjuvant comprises agent A and agent B, wherein agent A is an aluminum magnesium hydrotalcite nanoparticle (LDH) solution, and agent B is an okra polysaccharide RPS-1 solution.

[0008] Preferably, the mass ratio of the aluminum-magnesium hydrotalcite nanoparticles to the okra polysaccharide RPS-1 is 10 to 15:1.

[0009] Preferably, the molecular weight of the okra polysaccharide RPS-1 is 600 kDa.

[0010] Another object of the present invention is to provide a method for preparing the above-mentioned Newcastle disease DNA vaccine nanocomposite adjuvant, comprising the synthesis of aluminum-magnesium hydrotalcite nanoparticles and the extraction of okra polysaccharide RPS-1, and the specific steps are as follows:

[0011] S1. Synthesis of aluminum-magnesium hydrotalcite nanoparticles

[0012] S11, preparing a mixed solution of magnesium chloride hexahydrate and aluminum chloride hexahydrate to obtain solution a; preparing a sodium hydroxide solution to obtain solution b;

[0013] S12. Add solution a to solution b, mix well and centrifuge, discard the supernatant, repeat the process of "adding deionized water, centrifuging, discarding the supernatant" several times to purify the system, then add deionized water and transfer to a hydrothermal kettle, react under high temperature conditions to obtain an LDH solution.

[0014] S2. Extraction of Okra Polysaccharide RPS-1

[0015] S21. Take fresh okra fruit, wash and crush it, add deionized water to stir evenly, soak overnight, centrifuge to obtain supernatant and precipitate; extract the precipitate with distilled water twice, combine the supernatant, concentrate, collect the supernatant after centrifugation and add 95% ethanol to a final ethanol volume fraction of 65%, let stand overnight, centrifuge, re-dissolve the precipitate with distilled water, centrifuge at 4300r / min for 5min, and freeze-dry the supernatant to obtain okra water-soluble total polysaccharide (RPS);

[0016] S22. Take the freeze-dried crude polysaccharide (RPS) and deproteinize it with Sevag reagent to obtain deproteinized polysaccharide (DRPS); dissolve the deproteinized polysaccharide with distilled water, centrifuge, take the supernatant and apply it to a DEAE-Cellulose chromatography column (8.0×20cm), elute with distilled water and 0.25M PBS, and collect the eluate to obtain okra polysaccharide RPS-1 solution.

[0017] Preferably, in step S11, the content of magnesium chloride hexahydrate in solution a is 60-65 mg / mL, and the content of aluminum chloride hexahydrate is 24-25 mg / mL;

[0018] Preferably, in step S11, the content of sodium hydroxide in the solution b is 30-35 mg / mL.

[0019] Preferably, in step S12, the reaction under high temperature conditions refers to reacting at 110-130° C. for 13-16 hours.

[0020] Preferably, in step S22, the molecular weight of the okra polysaccharide RPS-1 is 600 kDa.

[0021] Another object of the present invention is to provide the application of the above-mentioned Newcastle disease DNA vaccine nanocomposite adjuvant in preventing and treating Newcastle disease, especially to provide the Newcastle disease DNA vaccine nanocomposite adjuvant as a loading agent for use in conjunction with the Newcastle disease nucleic acid vaccine.

[0022] The invention combines aluminum-magnesium hydrotalcite with okra polysaccharide RPS-1 in a composite form, which can be used as an immunopotentiator for Newcastle disease DNA vaccine. When used in combination with Newcastle disease vaccine nucleic acid vaccine, it can be used as a carrier to protect the DNA vaccine from degradation and increase its immune activity, thereby enhancing the immune function of animals, improving the disease resistance of animals and the protection rate of vaccines, and has great promotion value in preventing and controlling animal infectious diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Characterization of LDH and okra polysaccharide RPS-1. A, LDH scanning electron microscope (SEM) image; B, LDH particle size (PDI = 0.188); C, LDH zeta potential analysis; D, RPS-1 scanning electron microscope (SEM) image; E, RPS-1 particle size analysis (PDI = 0.331); F, RPS-1 zeta potential analysis.

[0024] Figure 2 The electrophoresis diagram of the recombinant plasmid and the recombinant plasmid digested with EcoRI-HindIII enzyme. 1: recombinant plasmid; 2: plasmid digested with EcoRI-HindIII enzyme; M: DNA Marker.

[0025] Figure 3 WB was used to identify the expression of HN protein after the recombinant plasmid was transfected into HEK293 cells.

[0026] Figure 4These are photos of HEK293 cells under ordinary and fluorescent microscopes after being transfected with the recombinant plasmid and cultured for 7 hours. A, 100X; B, 200X; C, 400X; D, fluorescent image.

[0027] Figure 5 These are photos and fluorescent images of HEK293 cells cultured for 12 hours after transfection with the recombinant plasmid. A and E are 100X; B and F are 200X; C and G are 400X.

[0028] Figure 6 The cytotoxicity of LDH and okra polysaccharide RPS-1 on RAW264.7 cells was analyzed.

[0029] Figure 7 These are the test results of serum HA-HI in different treatment groups.

[0030] Figure 8 is the serum IgG level in different treatment groups.

[0031] Fig. 9 It is the immune organ index of chickens 2 weeks after the first vaccination.

[0032] Fig.10 It is the immune organ index of chickens 2 weeks after the second vaccination. DETAILED DESCRIPTION

[0033] The following examples are used to further describe the specific embodiments of the present invention. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available, with analytically pure reagents being preferred reagents.

[0034] 1. Preparation of aluminum-magnesium hydrotalcite nanoparticles (50 nm)

[0035] 1. Prepare liquid a: weigh 609.63 mg (0.3 mmol) of magnesium chloride hexahydrate and 241.34 mg (0.1 mmol) of aluminum chloride hexahydrate to prepare 10 mL of solution.

[0036] Preparation of solution b: Weigh 320 mg (0.15 mmol) of sodium hydroxide to prepare 10 mL of solution and mix well using a heated magnetic stirrer.

[0037] 2. Add liquid a to liquid b, stir for 30 minutes, centrifuge at 4700r / min in a low-speed centrifuge for 5 minutes, pour out the supernatant, add 20mL of deionized water, centrifuge at the same speed for 5 minutes, pour out the supernatant, add 20mL of deionized water, centrifuge at the same speed for 5 minutes, pour out the supernatant, add 30mL of deionized water to the precipitate, transfer to a hydrothermal autoclave and react at 120°C for 15 hours to obtain an LDH nanoparticle solution, which is stored in a 4°C refrigerator.

[0038] The aluminum-magnesium hydrotalcite nanoparticles were scanned by scanning electron microscopy and showed a hexagonal sheet structure, such as Figure 1 The particle size of the particle is about 50 nm and the polydispersity index PDI value is 0.188. Figure 1 The zeta potential measurement results are shown in B. Figure 1 As shown in C.

[0039] 2. Extraction of Okra Polysaccharide RPS-1

[0040] 1. Take fresh okra fruit, wash with distilled water, crush with a tissue homogenizer, add distilled water, stir evenly, soak overnight, centrifuge at 4300r / min for 5min, and obtain supernatant and precipitate. The precipitate was extracted twice with distilled water, the supernatants after three centrifugations were combined, concentrated at 70℃, centrifuged at 4300r / min for 5min, the supernatant was collected and 95% ethanol was added to the final ethanol volume fraction of 65%, left to stand overnight, centrifuged at 4300r / min for 5min, the precipitate was re-dissolved with distilled water, centrifuged at 4300r / min for 5min, the supernatant was freeze-dried, and okra water-soluble total polysaccharide RPS was obtained.

[0041] 2. The lyophilized crude polysaccharide (RPS) was deproteinized with Sevag reagent to obtain deproteinized polysaccharide (DRPS). The DRPS sample was dissolved in distilled water, centrifuged, and the supernatant was applied to a DEAE-Cellulose chromatography column (8.0×20cm). It was eluted with distilled water and 0.25M PBS, and the eluate was collected to obtain the okra polysaccharide RPS-1 solution. After high-performance liquid gel permeation chromatography analysis, it was found that the elution peak of okra polysaccharide RPS-1 was a single and symmetrical peak, indicating that the molecular weight of okra polysaccharide RPS-1 was 600kDa.

[0042] The scanning electron microscope scanning results of okra polysaccharide RPS-1 are as follows: Figure 1 The particle size measured by DSL particle size analyzer is about 594nm, and its polydispersity index PDI value is 0.331. Figure 1 The zeta potential was measured to be -32 mV. Figure 1 3. Construction and expression of Newcastle disease DNA recombinant vector

[0043] 1. We commissioned Shanghai Bioengineering to synthesize the recombinant vector, using the pcDNA3.1(-) vector, inserting the HN gene sequence, adding EGFP to the N-terminus of the recombinant protein fragment, and adding His and Flag purification tags to the C-terminus.

[0044] The recombinant vector was digested with restriction endonucleases EcoR I-HindIII and then run for electrophoresis for identification. The electrophoresis diagram of the recombinant plasmid after digestion was ( Figure 2 ), the results showed that the first lane was pcDNA3.1, which showed only one band at about 4500bp, and the second lane was the recombinant vector after enzyme digestion, which showed two bands at about 5500bp and 2400bp respectively, indicating that the HN gene was successfully inserted.

[0045] 2. The recombinant vector was digested with restriction endonucleases EcoR I-HindIII and then transfected into mammalian HEK293 cells. After culture, the cell samples were collected, proteins were extracted, and WB was detected with anti-Flag antibody (protein was passed through a His-labeled FF column, and anti-EGFP antibody was used for WB. The transfection concentrations of 1# and 2# were 2*10 6 and 2.5*10 6 ),like Figure 3 As shown, after 48 hours and 72 hours of culture, the target band was detected by anti-tag protein antibody at 72-95KD, confirming that the target protein was expressed in the transfected cells. The photos of HEK293 cells under ordinary and fluorescent microscopes 7 hours and 12 hours after transfection are shown in Figure 4 , 5 As shown, the results also showed that green fluorescent protein could be expressed 7 hours and 12 hours after transfection, indicating that the protein could be successfully expressed in eukaryotic cells after transfection of the recombinant vector.

[0046] 4. The toxicity of LDH and okra polysaccharide RPS-1 was evaluated

[0047] LDH and okra polysaccharide RPS-1 were added to RAW264.7 cells at different concentrations, and the cell viability was measured by CCK-8 method at 24 hours and 48 hours after culture. The results are shown in Figure 6 shown.

[0048] 5. Verification of immune effect

[0049] 1. One hundred and eighty one-day-old Wenchang chickens were divided into 6 groups, with 30 chickens in each group, including PBS group, empty plasmid pcDNA3.1 group, pcDNA3.1-HN group, pcDNA3.1-HN+LDH group, pcDNA3.1-HN+LDH+RPS-1 group, and commercial vaccine (LaSota vaccine) group for immunization (injection).

[0050] The preparation process of pcDNA3.1-HN+LDH+RPS-1 is as follows:

[0051] The LDH solution was mixed with the plasmid solution at a ratio of plasmid:LDH=15:1 (mass ratio), oscillated on an oscillator for 30 seconds, and incubated at room temperature for 30 minutes to obtain a pcDNA3.1-HN-LDH solution; the okra polysaccharide RPS-1 solution was added to the prepared pcDNA3.1-HN-LDH solution at a ratio of LDH: okra polysaccharide RPS-1=12:1 (mass ratio), oscillated on an oscillator for 30 seconds, and incubated at room temperature for 30 minutes.

[0052] 2. The first and second vaccinations were carried out at 28 days and 42 days of age, respectively. Blood samples were collected at 7, 14, 28, and 35 days after the first vaccination to measure the Newcastle disease HI antibody titer, and the serum IgG levels were measured 2 weeks after the first and second vaccinations. Figure 7 , 8 Five chickens were slaughtered 2 weeks after the first vaccination and 2 weeks after the second vaccination to measure their immune organ indexes. Figure 9-10 shown.

[0053] Although the objectives, technical solutions, beneficial effects and specific implementation plans of the present invention have been described in detail above, modifications or improvements to the above contents are obvious to professionals in the field and should therefore be included in the scope of protection of the present invention.

Claims

1. A Newcastle disease DNA vaccine nanocomposite adjuvant, characterized in that: The method comprises agent A and agent B, wherein agent A is an aluminum-magnesium hydrotalcite nanoparticle solution, and agent B is an okra polysaccharide RPS-1 solution.

2. The Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 1, characterized in that: The mass ratio of the aluminum-magnesium hydrotalcite nanoparticles to the okra polysaccharide RPS-1 is 10-15:

1.

3. The Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 1, characterized in that: The molecular weight of the okra polysaccharide RPS-1 is 600 kDa.

4. A method for preparing the Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 1, characterized in that: The method includes the synthesis of aluminum-magnesium hydrotalcite nanoparticles and the extraction of okra polysaccharide RPS-1, and the specific steps are as follows: S1. Synthesis of aluminum-magnesium hydrotalcite nanoparticles S11, preparing a mixed solution of magnesium chloride hexahydrate and aluminum chloride hexahydrate to obtain solution a; preparing a sodium hydroxide solution to obtain solution b; S12, adding solution a to solution b, mixing and centrifuging, discarding the supernatant, repeating the process of "adding deionized water, centrifuging, discarding the supernatant" several times to purify the system, then adding deionized water and transferring to a hydrothermal kettle, reacting under high temperature conditions, to obtain an LDH solution; S2. Extraction of Okra Polysaccharide RPS-1 S21. Take fresh okra fruit, wash and crush, add deionized water and stir evenly, soak overnight, centrifuge to obtain supernatant and precipitate; extract the precipitate with distilled water twice, combine the supernatant, concentrate, collect the supernatant after centrifugation and add 95% ethanol to a final ethanol volume fraction of 65%, let stand overnight, centrifuge, re-dissolve the precipitate with distilled water, centrifuge at 4300r / min for 5min, freeze-dry the supernatant to obtain okra water-soluble total polysaccharides; S22. Deproteinize the lyophilized crude polysaccharide with Sevag reagent to obtain deproteinized polysaccharide; dissolve the deproteinized polysaccharide with distilled water, centrifuge, take the supernatant and apply it to a DEAE-Cellulose chromatography column, elute with distilled water and 0.25M PBS, and collect the eluate to obtain the okra polysaccharide RPS-1 solution.

5. The method for preparing the Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 4, characterized in that: In the step S11, the content of magnesium chloride hexahydrate in the solution a is 60-65 mg / mL, and the content of aluminum chloride hexahydrate is 24-25 mg / mL.

6. The method for preparing the Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 4, characterized in that: In the step S11, the content of sodium hydroxide in the solution b is 30-35 mg / mL.

7. The method for preparing the Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 4, characterized in that: In the step S12, the reaction under high temperature conditions refers to reacting at 110-130° C. for 13-16 hours.

8. The method for preparing the Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 4, characterized in that: In the step S22, the molecular weight of the okra polysaccharide RPS-1 is 600 kDa.

9. Use of the Newcastle disease DNA vaccine nanocomposite adjuvant according to claim 1 in preventing and treating Newcastle disease.

10. The use according to claim 9, characterized in that: The Newcastle disease DNA vaccine nanocomposite adjuvant is used as a loading agent in combination with the Newcastle disease nucleic acid vaccine.

Citation Information

Patent Citations

  • DNA-programmed layered double-metal hydroxide vaccine adjuvant and preparation method thereof

    CN117205310A

  • Individualized anti-tumor nano vaccine based on inorganic nano adjuvant and application of individualized anti-tumor nano vaccine

    CN117838846A

  • Novel pestilence DNA vaccine and its construction and application

    CN1565630A

  • Vaccine composition comprising a hydrotalcite-type compound

    WO2003000284A1